Abstract
The lysosomal storage disorders (LSD) are a group of about 50 diseases that are characterised by an accumulation of waste products in the lysosomes, resulting in the formation of large intracellular vacuoles (Fig. 1).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
De Duve C. Lysosomes, a new group of cytoplasmic particles. In: Hayashi T, ed. Subcellular Particles. Ronald Press, 1959:128–159.
Meikle PJ, Hopwood JJ, Clague AE et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281(3):249–54.
Poorthuis BJ, Wevers RA, Kleijer WJ et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Gen 1999; 105:151–156.
Raychowdhury MK, Gonzalez-Perrett S, Montalbetti N et al. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum Mol Genet 2004; 13(6):617–27.
Masson C, Cisse I, Simon V et al. Fabry disease: A review. Joint Bone Spine 2004; 71(5):381–3.
Hopwood JJ, Bunge S, Morris CP et al. Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate-2-sulphatase gene. Hum Mutat 1993; 2(6):435–42.
Nishino I, Fu J, Tanji K et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406(6798):906–10.
Ikonen E, Peltonen L. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease. Hum Mutat 1992:1(5):361–5.
Varho TT, Alajoki LE, Posti KM et al. Phenotypic spectrum of Salla disease, a free sialic acid storage disorder. Pediatr Neurol 2002; 26(4):267–73.
Horowitz M, Pasmanik-Chor M, Borochowitz Z et al. Prevalence of glucocerebrosidase mutations in the israeli ashkenazi Jewish population. Hum Mutat 1998; 12(4):240–4.
Myerowitz R. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat 1997; 9(3):195–208.
Beutler E, Grabowski GA. Gaucher disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3635–3668.
Gravel RA, Kaback MM, Proia RL et al. The GM2 Ganglisiodosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3827–3876.
Hirshhorn R, Reuser A. Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3389–3420.
Beta-galactosidase deficiency (beta-galactosidosis). In: Suzuki Y, Oshima A, Nanba E, Schriver CR, Beaudet AL, Sly WS, Valle D, eds. GM1 gangliosidosis and Morquio B disease. 2001:3775–3809.
Patterson JS, Jones MZ, Lovell KL et al. Neuropathology of bovine beta-mannosidosis. J Neuropathol Exp Neurol 1991; 50(5):538–46.
Boyer PJ, Jones MZ, Rathke EJ et al. Regional central nervous system oligosaccharide storage in caprine beta-mannosidosis. J Neurochem 1990; 55(2):660–4.
Bedilu R, Nummy KA, Cooper A et al. Variable clinical presentation of lysosomal beta-mannosidosis in patients with null mutations. Mol Genet Metab 2002; 77(4):282–90.
Bijsterbosch MK, Donker W, van de Bilt H et al. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 1996; 237(2):344–9.
Zhu Y, Li X, Kyazike J et al. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in Pompe mice. J Biol Chem 2004, [Epub ahead of print].
Whittington R, Goa KL. Alglucerase. A review of its therapeutic use in Gaucher’s disease. Drugs 1992; 44(1):72–93.
Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122:33–39.
Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry’s disease: Recent advances and clinical applications. J Nephrol 2004; 17(3):354–63.
Wraith JE, Clarke LA, Beck M et al. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144(5):581–8.
Van den Hout JM, Kamphoven JH, Winkel LP et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113(5):e448–57.
Lachmann RH. alpha-glucosidase (CHO) (Genzyme). Curr Opin Investig Drugs 2004; 5(10):1101–10.
Muenzer J, Lamsa JC, Garcia A et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): A preliminary report. Acta Paediatr Suppl 2002; 91(439):98–9.
Harmatz P, Whitley CB, Waber L et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144(5):574–80.
Bae JS, Jang KH, Schuchman TR et al. Comparative effects of recombinant acid sphingomyelinase administration by different routes in niemann-pick disease mice. Exp Anim 2004; 53(5):417–21.
Roces DP, Lullmann-Rauch R, Peng J et al. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: A preclinical animal study. Hum Mol Genet 2004; 13(18):1979–88.
Hoogerbrugge PM, Brouwer OF, Bordigoni P et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995; 345(8962):1398–402.
Zheng Y, Rozengurt N, Ryazantsev S et al. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab 2003; 79(4):233–44.
Barranger JM, Novelli EA. Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2001; 1(5):857–67.
Mandel RJ, Burger C. Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Curr Opin Mol Ther 2004; 6(5):482–90.
Elstein D, Hollak C, Aerts JM et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27(6):757–66.
Meikle PJ, Ranieri E, Simonsen H et al. Newborn screening for lysosomal storage disorders: Clinical evaluation of a two-tier strategy. Pediatrics 2004; 114(4):909–16.
Aronson NN, Kuranda MJ. Lysosomal degradation of Asn-linked glycoproteins. FASEB J 1989; 3:2615–2622.
Thomas G. Disorders of glycoprotein degradation: alpha-mannosidosis, beta-Mannosidosis, Fucosidosis and Sialidosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3507–3534.
Desnick RJ, Schindler L. Alpha-N-acetylgalactosaminidase deficiency: Schindler disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3483–3506.
Sakuraba H, Matsuzawa F, Aikawa S et al. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet 2004; 49:1–8.
d’Azzo A, Andria G, Strisiugli P et al. Galactosialidosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001; 3811–3826.
Aula P, Jalanko A, Peltonen L. Aspartylglucosaminuria. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3535–3550.
von Figura K, Gieselman V, Jaeken J. Metachromatic leukodystrophy. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3695–3724.
Sonnino S, Chigorno V. Ganglioside molecular species containing C18-and C20-sphingosine in mammalian nervous tissues and neuronal cell cultures. Biochim Biophys Acta 2000; 1469:63–77.
Coetzee T, Suzuki K, Popko B. New perspectives on the function of myelin galactolipids. Trends Neurosci 1998; 21:126–130.
Desnick RJ, Ioannou YA, Eng CM. alpha-Galactosidase A deficiency; Fabry Disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3507–3534.
Wenger DA, Suzuki K, Suzuki Y et al. Galactosylceramide lipidosis: Globoid cell leukodystrophy (Krabbe disease). In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3669–3694.
Dierks T, Schmidt B, Borissenko LV et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 2003; 113(4):435–44.
Neufeld E, Muenzer J. The Mucopolysaccharidoses. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3669–3694.
Schuchman EH, Desnick RJ. Niemann-Pick Disease Types A and B: Acid sphingomyelinase Deficiencies. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3589–3610.
Moser HW, Linke T, Fensom AH et al. Acid ceramidase deficiency: Farber lipogranulomatosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3573–3588.
Assmann G, Seedorf U. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3551–3572.
Gelb BD, Bromme D, Desnick RJ. Pycnodysostosis: Cathepsin K deficiency In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3453–3468.
Hofmann SJ, Peltonen L. The neuronal ceroid lipofuscinoses. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3877–3896.
Kopan S, Sivasubramaniam U, Warburton MJ. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: Evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. Biochem Biophys Res Commun 2004; 319(1):58–65.
Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16(1):76–81.
Aula P, Gahl WA. Disorders of free sialic acid storage. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:5109–5120.
Gahl WA, Thoene JG, Schneider JA. Cystinosis: A disorder of lysosomal memmbrane transport. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:5085–5108.
Raas-Rothschild A, Cormier-Daire V, Bao M et al. Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC). J Clin Invest 2000; 105(5):673–81.
Kornfeld S, Sly WS. I-Cell Disease and pseudo-hurler polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Meta-bolic and Molecular Bases of Inherited Disease. 2001:3469–3482.
Bach G. Mucolipidosis type IV. Mol Genet Metab 2001:73(3):197–203.
Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep 2003; 3(1):64–9.
Nishino I, Fu J, Tanji K et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406(6798):906–10.
Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: Emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003; 13(3):137–45.
Patterson MC, Vanier MT, Suzuki K et al. Niemann-pick disease type c: A lipid trafficking disorder. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3611–3634.
Sturley SL, Patterson MC, Balch W et al. The pathophysiology and mechanisms of NP-C disease. Biochim Biophys Acta 2004; 1685(1–3):83–7.
Hofman SL, Peltonen L. The neuronal ceroid lipofuscinoses In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. 2001:3877–3896.
Luiro K, Yliannala K, Ahtiainen L et al. Interconnections of CLN3, Hookl and Rab proteins link Batten disease to defects in the endocytic pathway. Hum Mol Genet 2004; 13(23):3017–27.
Mole SE, Michaux G, Codlin S et al. CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp Cell Res 2004; 298(2):399–406.
Winter E, Ponting CP. TRAM, LAG1 and CLN8: Members of a novel family of lipid-sensing domains? Trends Biochem Sci 2004; 27(8):381–3.
Stinchcombe J, Bossi G, Griffiths GM. Linking albinism and immunity: The secrets of secretory lysosomes. Science 2004; 305(5680):55–9.
Huizing M, Gahl WA. Disorders of vesicles of lysosomal lineage: The Hermansky-Pudlak syndromes. Curr Mol Med 2002; 2(5):451–67.
Triggs-Raine B, Salo TJ, Zhang H et al. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci 1999; 96:6296–300.
Tomita Y, Suzuki T. Genetics of pigmentary disorders. Am J Med Genet 2004; 131C(1):75–81.
Clark RH, Stinchcombe JC, Day A et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 2003; 4(11):1111–20, Epub 2003.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2005 Eurekah.com and Springer Science+Business Media
About this chapter
Cite this chapter
Greiner-Tollersrud, O.K., Berg, T. (2005). Lysosomal Storage Disorders. In: Lysosomes. Medical Intelligence Unit. Springer, Boston, MA. https://doi.org/10.1007/0-387-28957-7_6
Download citation
DOI: https://doi.org/10.1007/0-387-28957-7_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25562-0
Online ISBN: 978-0-387-28957-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)